Immutep Fast Tracked for Non-Small Cell Lung Cancer Therapy

• Fast Track designation has been granted by the US FDA for efti in combination with pembrolizumab in 1st line non-small cell lung cancer

• Based on the encouraging Phase II clinical data for PD-L1 all-comers presented at ASCO 2022

• Marks the second Fast Track designation issued by the FDA for eftilagimod alpha, offering the potential for expedited development and review

https://finance.yahoo.com/news/immutep-receives-fda-fast-track-120000746.html